News

J. D. Jobson, Bob Korkie, Statistical Inference in Two-Parameter Portfolio Theory with Multiple Regression Software, The Journal of Financial and Quantitative Analysis, Vol. 18, No. 2 (Jun., 1983), pp ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations.
Full transcript - Recursion Pharmaceuticals Inc (RXRX) Q2 2025: Chris Gibson, Co-Founder and CEO, Recursion Pharmaceuticals: Recursion’s q two twenty twenty five earnings call.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ETCompany ParticipantsBen R.
Recursion Pharmaceuticals is expected to provide updates regarding the clinical-stage pipeline programs on its second-quarter earnings call.
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Tuesday reported a loss of $171.9 million in its second quarter.
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Tuesday reported a loss of $171.9 million in its second quarter.
From a technology perspective, Recursion continued the rollout of Recursion OS 2.0, a platform upgrade integrating Exscientia’s AI-driven chemistry capabilities and large-scale multimodal ...
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Tuesday reported a loss of $171.9 million in its second quarter.
The company also collaborated with NVIDIA Corporation, the global leader in visual computing technologies, to develop a next-generation platform for the creation of novel therapies. Recursion ...
From a technology perspective, Recursion continued the rollout of Recursion OS 2.0, a platform upgrade integrating Exscientia’s AI-driven chemistry capabilities and large-scale multimodal ...
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -17.14% and +33.71%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for ...